Gainers
- Akanda (NASDAQ:AKAN) shares rose 66.8% to $3.42 during Wednesday's regular session. The market value of their outstanding shares is at $5.4 million.
- Cue Biopharma (NASDAQ:CUE) shares rose 47.7% to $4.18. The company's market cap stands at $23.6 million. As per the press release, Q3 earnings came out 2 days ago.
- Icecure Medical (NASDAQ:ICCM) stock increased by 25.28% to $1.04. The market value of their outstanding shares is at $2.8 million. As per the press release, Q3 earnings came out today.
- AN2 Therapeutics (NASDAQ:ANTX) stock rose 22.15% to $5.17. The company's market cap stands at $160.5 million.
- DataMEDS AI (NASDAQ:MEDS) stock rose 21.83% to $0.78. The company's market cap stands at $2.0 million. As per the news, the Q3 earnings report came out 3 days ago.
- Tiziana Life Sciences (NASDAQ:TLSA) stock moved upwards by 21.66% to $0.79. The company's market cap stands at $82.4 million.
Losers
- Prenetics Global (NASDAQ:PRE) shares fell 38.3% to $10.08 during Wednesday's regular session. The company's market cap stands at $274.0 million. The company's, Q3 earnings came out today.
- Iridex (NASDAQ:IRIX) shares fell 28.26% to $0.5. The company's market cap stands at $12.1 million. The company's, Q3 earnings came out yesterday.
- CEL-SCI (AMEX:CVM) stock decreased by 24.87% to $1.39. The market value of their outstanding shares is at $32.5 million.
- Quanterix (NASDAQ:QTRX) shares fell 23.79% to $2.18. The market value of their outstanding shares is at $135.7 million.
- Innate Pharma (NASDAQ:IPHA) stock decreased by 21.88% to $1.04. The market value of their outstanding shares is at $148.5 million.
- Ardent Health (NYSE:ARDT) stock decreased by 19.55% to $14.28. The company's market cap stands at $2.5 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Share this article


